Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 06/23–06/24 | 06/24 | 39,363 sh2 trades | $69.92avg. | $2,752,269.72 | −82.4% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 06/22–06/23 | 06/24 | 5,004 sh2 trades | $68.25avg. | $341,523.72 | −35.1% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 06/15 | 06/17 | 90,240 sh2 trades | $66.63avg. | $6,012,570.36 | −93.2% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 06/04–06/05 | 06/08 | 80,000 sh14 trades | $67.67avg. | $5,413,290.72 | −1.8% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 05/21 | 05/26 | 26,103 sh5 trades | $69.44avg. | $1,812,475.26 | −9.7% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 05/18 | 05/19 | 13,651 sh2 trades | $65.08avg. | $888,468.17 | −3.7% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 05/15 | 05/19 | 10,000 sh4 trades | $67.15avg. | $671,468.4 | −46.3% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 05/07–05/08 | 05/11 | 80,000 sh12 trades | $67.40avg. | $5,392,321.3 | −1.8% | |
Maricel ApuliChief Accounting Officer | BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 04/30 | 05/04 | 2,000 sh | $71.58 | $143,160 | −1.5% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 04/09–04/10 | 04/13 | 80,000 sh8 trades | $74.61avg. | $5,968,524.04 | −1.8% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 03/12–03/13 | 03/16 | 80,000 sh10 trades | $68.76avg. | $5,501,136.18 | −1.8% | |
Hannah ValantineDirector | BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 03/10 | 03/12 | 8,671 sh | $72.00 | $624,312 | −53.7% |
Andrea EllisDirector | BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 03/04 | 03/06 | 64,921 sh | $64.87 | $4,211,425.27 | −77.7% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 02/27 | 03/03 | 25,484 sh2 trades | $67.41avg. | $1,717,750.72 | −77.3% | |
Maricel ApuliChief Accounting Officer | BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 02/26 | 02/27 | 2,000 sh | $66.00 | $132,000 | −1.6% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 02/19 | 02/23 | 28,053 sh3 trades | $71.39avg. | $2,002,624.53 | −10.7% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 02/17 | 02/18 | 10,000 sh3 trades | $75.46avg. | $754,553.52 | −46.3% | |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 02/17 | 02/18 | 13,600 sh2 trades | $74.72avg. | $1,016,190 | −3.9% | |
Maricel ApuliChief Accounting Officer | BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 02/17 | 02/18 | 510 sh | $74.31 | $37,898.1 | −0.4% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 02/10–02/11 | 02/12 | 80,000 sh12 trades | $71.86avg. | $5,748,697.51 | −1.8% |